Sirana enters into collaborative research agreement with Pfizer
Companies will combine to investigate a novel treatment for a rare bone disease
30th June 2022
Latest news
Atos opens Life Science Centre of Excellence
Centre will accelerate drug development and enable precision health solutions
30th June 2022
First treatment for ‘broken heart syndrome’ trialled
Scientists will trial a programme of exercise conditioning and psychological therapy for people diagnosed with the condition
29th June 2022
Avacta announces escalation in clinical study of AVA6000
AVA6000 is a novel form of doxorubicin that has been modified using Avacta’s delivery platform to improve safety
29th June 2022
Amref and AstraZeneca launch clinics to support Kenyan COVID-19 vaccinations
The mobile clinics will support communities with limited or no access to vaccines and other health services
28th June 2022
Novo Nordisk to build on heritage in rare blood disorders
New data will be released at the International Society on Thrombosis and Haemostasis Congress
28th June 2022
AbbVie’s Rinvoq gains recommended approval by CHMP
CHMP returns positive opinion on Rinvoq for the treatment of adults with active non-radiographic axial spondyloarthritis
27th June 2022
EU approves Norvatis’ Cosentyx for childhood arthritis
Cosentyx receives expanded approvals in EU for use in childhood arthritic conditions
27th June 2022
Sanofi and GSK report successful efficacy results against Omicron
COVID-19 Beta-containing vaccine provides 75.1% efficacy in participants previously infected with coronavirus
24th June 2022
Positive MHRA decision for Briviact
MHRA extends UCB’s therapy for the treatment of partial-onset seizures
24th June 2022
Pharma poised but no recorded monkeypox deaths
Global surveillance systems show that recorded cases do not include any deaths
23rd June 2022
Novartis invests $250m in malaria elimination commitment
The company has renewed its pledge to eliminate neglected tropical diseases and malaria over five years
23rd June 2022
Novartis lung cancer drug Tabrecta gets approval
Novartis receives approval from the European Commission for Tabrecta for the treatment of non-small cell lung cancer
22nd June 2022
NICE opts to reject Acorda’s MS drug Fampyra
The MS Society responds as MS therapy Fampyra is rejected
22nd June 2022
AstraZeneca’s Eplontersen meets endpoints in critical phase 3 trial
Eplontersen significantly improved patient-reported quality of life following successful research
21st June 2022
